In most cancer types, the frequency of alterations did not exceed 5% for each of the tested genes (Figure S1B–E), except for TRIM24 in Ovarian Serous Cystadenocarcinoma (OV) (10.98%) and SKCM (8.05%), and TRIM28 and TRIM33 in Esophageal Carcinoma (ESCA) (5.41% and 5.41% of altered samples, respectively), suggesting that genetic alterations in TIF1 members are not of great importance in cancer development. Here, TRIM33 is linked to ovarian serous cystadenocarcinoma.